Research progress of Chinese medicine in the treatment of primary liver cancer

Research Article
Open access

Research progress of Chinese medicine in the treatment of primary liver cancer

Zibo Hong 1*
  • 1 Xiamen Hospital of Traditional Chinese Medicine, Xiamen, China    
  • *corresponding author 919658962@qq.com
JCTT Vol.3 Issue 2
ISSN (Print): 3049-5466
ISSN (Online): 3049-5458

Abstract

Primary liver cancer is a refractory tumor with a high recurrence rate and low quality of life. Traditional Chinese medicine, especially Chinese patent medicines, has shown positive therapeutic prospects in improving symptoms and quality of life. This study summarizes the potential efficacy of various Chinese patent medicines for primary liver cancer through a literature review, and describes their mechanism of action through multiple pathways, such as regulating the tumor immune microenvironment, modulating metabolic patterns, and inhibiting tumor cell growth and proliferation. Despite considerable advancements in the clinical utilization of Chinese patent medicines, existing research exhibits limitations, including the necessity to enhance the comprehensiveness of clinical data and the profundity of mechanistic investigations. Future research trajectories should encompass broadening the scope of clinical studies, intensifying the exploration of the mechanisms underlying Chinese patent medicines, and fostering the standardization and personalization of treatment protocols.

Keywords:

primary liver cancer, Chinese patent medicines, tumor immune microenvironment, tumor cell apoptosis

Hong,Z. (2025). Research progress of Chinese medicine in the treatment of primary liver cancer. Journal of Clinical Technology and Theory,3(2),10-14.
Export citation

References

[1]. Zhou, Y., & Zhou, Y. (2024). A preliminary study on the treatment of primary liver cancer with the kidney-tonifying and phlegm-resolving formula. Chinese Medicine Clinical Research, 16(8), 111-117.

[2]. Shao, Y., & Su, R. (2023). Combination of drugs in the tumor immune microenvironment of liver cancer. Acupuncture and Herbal Medicine, 3(3), 189-199.

[3]. Pang, H., Hu, K., & Zhou, T. (2021). Research on the regulation of tumor metabolism by blood-activating drugs. Electronic Journal of Tumor Metabolism and Nutrition, 8(1), 87-92.

[4]. Lu, R., & Yi, L. (2024). A brief analysis of “excessive harm and tolerance” and primary liver cancer. Chinese Medicine Clinical Research, 16(5), 77-81.

[5]. Zhao, M., & Zhang, G. (2021). Entry points and difficulties in the treatment of primary liver cancer with traditional Chinese medicine. Journal of Clinical Hepatology, 37(9), 2016-2024.

[6]. Chinese Society of Traditional Chinese Medicine Hepatobiliary Disease Branch, Li, X., & Wang, X. (2024). Guidelines for the diagnosis and treatment of primary liver cancer with traditional Chinese medicine. Journal of Integrated Traditional Chinese and Western Medicine in Hepatology, 34(4), insert 1-insert 6.

[7]. Zhao, Q., Tian, T. (2016). Traditional Chinese medicine intervention in the tumor immune microenvironment. Modern Oncology, 2, 306-309.

[8]. Deng, L., & Rao, B. Q. (2017). Regulation of mitochondrial metabolism: anti-tumor mechanism of the traditional Chinese medicine compound JC724 for clearing away heat and detoxifying. Oncology Metabolism and Nutrition e-Journal, 4(4), 445-452.

[9]. Mao, H., Zhu, H. (2023). Research progress of tumor metabolism in metastasis. Journal of Bengbu Medical College, 48(1), 37-44.

Cite this article

Hong,Z. (2025). Research progress of Chinese medicine in the treatment of primary liver cancer. Journal of Clinical Technology and Theory,3(2),10-14.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Journal：Journal of Clinical Technology and Theory

Volume number: Vol.3
Issue number: Issue 2
ISSN：3049-5458(Print) / 3049-5466(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).

References

[1]. Zhou, Y., & Zhou, Y. (2024). A preliminary study on the treatment of primary liver cancer with the kidney-tonifying and phlegm-resolving formula. Chinese Medicine Clinical Research, 16(8), 111-117.

[2]. Shao, Y., & Su, R. (2023). Combination of drugs in the tumor immune microenvironment of liver cancer. Acupuncture and Herbal Medicine, 3(3), 189-199.

[3]. Pang, H., Hu, K., & Zhou, T. (2021). Research on the regulation of tumor metabolism by blood-activating drugs. Electronic Journal of Tumor Metabolism and Nutrition, 8(1), 87-92.

[4]. Lu, R., & Yi, L. (2024). A brief analysis of “excessive harm and tolerance” and primary liver cancer. Chinese Medicine Clinical Research, 16(5), 77-81.

[5]. Zhao, M., & Zhang, G. (2021). Entry points and difficulties in the treatment of primary liver cancer with traditional Chinese medicine. Journal of Clinical Hepatology, 37(9), 2016-2024.

[6]. Chinese Society of Traditional Chinese Medicine Hepatobiliary Disease Branch, Li, X., & Wang, X. (2024). Guidelines for the diagnosis and treatment of primary liver cancer with traditional Chinese medicine. Journal of Integrated Traditional Chinese and Western Medicine in Hepatology, 34(4), insert 1-insert 6.

[7]. Zhao, Q., Tian, T. (2016). Traditional Chinese medicine intervention in the tumor immune microenvironment. Modern Oncology, 2, 306-309.

[8]. Deng, L., & Rao, B. Q. (2017). Regulation of mitochondrial metabolism: anti-tumor mechanism of the traditional Chinese medicine compound JC724 for clearing away heat and detoxifying. Oncology Metabolism and Nutrition e-Journal, 4(4), 445-452.

[9]. Mao, H., Zhu, H. (2023). Research progress of tumor metabolism in metastasis. Journal of Bengbu Medical College, 48(1), 37-44.

For authors
Guide for authors Policies for authors Aims and scope Subscription Open access policy
For editors
Policies for editors Editorial board
For reviewers
Policies for reviewers Privacy policy

Cookies are used by this site.
Copyright © 2024 EWA Publishing, its licensors, and contributors. All rights reserved, including text and data mining, AI training, and similar technologies.